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INTRODUCTION
Lung transplantation is the only treatment option for end-
stage lung disease (ESLD) that cannot be effectively managed 
using non-surgical treatment [1]. Human lung transplanta-
tion was performed for the first time in 1962 by Hardy et al. [2]. 
However, successful lung transplantation was first achieved 
in 1983 aided by advances in many fields such as immuno-
suppression, organ preservation techniques, and anesthetic 
methods [3]. Since then, lung transplantation is being per-
formed frequently. According to the annual report of the 
International Society for Heart and Lung Transplantation, 
64,803 adult lung transplantations were performed until June 
2017, and over 4,500 lung transplantations were performed in 
2016 [4]. In Korea, since the first lung transplantation in 1996, 
640 lung transplants have been carried out until 2019, and 
more than 90 lung transplants have been performed annually 
since 2016. Although the number of patients receiving organ 
transplantation is constantly rising, organ donation is always 
insufficient compared to the number of patients waiting for 
transplantation. With a change in the society’s perception of 
organ donation, more people are agreeing to donate their or-
gans after death. However, in most of the brain-dead patients, 
the brain death is caused by head damage or cerebral hemor-
rhage. Unfortunately, such cases are often accompanied by 
pulmonary parenchymal damage. Therefore, only 15–20% 
of the lungs from the brain-dead donors are suitable for lung 
transplantation [5,6]. The utilization rate is lower than 15% 
in Korea. The shortage of donated organs is expected to im-
prove with recent legal approval of living-donor lung trans-
plantation. However, in many countries where living-donor 
lung transplantation has already been approved, shortage of 
donated lungs is still encountered. 
INDICATIONS FOR LUNG 
TRANSPLANTATION
The primary purpose of lung transplantation is to alleviate 
dyspnea and to improve quality of life in patients with ESLD. 
While deciding whether to perform lung transplantation, 
it is important to make a judgment regarding the timing of 
the transplantation, considering the underlying disease and 
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Since the first lung transplantation, developments in surgical techniques, immunosup-
pressants, preservation solutions, monitoring devices, anesthetic agents, and drugs 
and devices for hemodynamic support have resulted in improved survival rates after 
lung transplantation. Lung transplantation is a high-risk procedure and end-stage lung 
disease is frequently accompanied by compromised cardiopulmonary function. There-
fore, a highly trained cardiothoracic anesthesiologist is required during the procedure. 
As various factors related to anesthesia may have important effects on the prognosis of 
the patient after the lung transplantation, an anesthesiologist must not only be familiar 
with the use of various medications and monitoring devices, but also understand the 
patient’s pathophysiology and the surgical procedure.
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its progression. The timing of the recommendation of lung 
transplantation to the patient is not determined by a single 
factor but is decided based on a comprehensive consider-
ation of several factors such as the severity of infection, ad-
mission frequency, oxygen demand, level of carbon dioxide 
in the bloodstream, pulmonary function, exercise capacity, 
pulmonary arterial pressure, and New York Heart Association 
Functional Classification [7]. Patients with chronic respirato-
ry diseases showing functional problems and patients whose 
survival is predicted to be less than 1–2 years without trans-
plantation should be referred to a lung transplant specialist. 
After the need for lung transplantation has been determined, 
the patient needs several necessary tests and should wait for 
a certain period before the transplantation. Therefore, a deci-
sion about whether to transplant should be made before the 
condition of the patient deteriorates further. There are four 
major types of diseases that may require lung transplantation: 
chronic obstructive pulmonary disease (COPD), inflamma-
tory lung diseases such as bronchiectasis, lung parenchymal 
diseases that may be caused by pulmonary fibrosis or chemo-
therapy, and primary or secondary pulmonary arterial hyper-
tension caused by complications of congenital heart disease 
[8]. Although COPD is the most common indication for lung 
transplantation worldwide, the most common reason for 
lung transplantation in Korea is idiopathic pulmonary fibro-
sis (IPF), followed by lymphangioleiomyomatosis, COPD, 
and primary pulmonary hypertension [8]. Until 2018, only 
the lungs procured from brain-dead patients were allowed to 
be transplanted in Korea, and procuring lungs such as liver 
or kidney from the living body was forbidden. Improvements 
in this scenario are expected due to the recent legal approval. 
However, till date, nearly all the transplanted lungs have been 
procured from a brain-dead donor. The standard lung donor 
criteria are listed in Table 1 [9].
PROGNOSIS AFTER LUNG 
TRANSPLANTATION AND CURRENT 
STATUS IN KOREA
The median survival time for adult lung transplant re-
cipients was reported to be 5.6 years. However, the median 
survival time was 7.9 years in patients who survived for more 
than one year. Thus, the complications and the mortality rate 
were higher in the first year after transplantation [10]. The 
survival rate after lung transplantation in Korea is lower than 
that reported by the International Society for Heart and Lung 
Transplantation. The reason for this may be the lack of surgi-
cal experience of lung transplantation in Korea. Another rea-
son may be that the patients had undergone the lung trans-
plantation after their condition had deteriorated. With the 
increase in the number of the lung transplantations in Korea 
and with the surgery being carried out before worsening of 
the patients’ condition, the survival rate after lung transplan-
tation became similar to that at the global level [8]. Globally, 
the survival rate after lung transplantation has remained 
almost unchanged in recent years, despite many advances in 
the related fields. 
The one-year mortality rate of 20–30% after lung transplan-
tation is usually due to failure of lung function. Postoperative 
primary graft dysfunction (PGD) is known to be closely asso-
ciated with ischemia/reperfusion injury and a potent activa-
tion of inflammation [11]. A recent cohort study reported that 
the incidence of PGD (partial pressure of oxygen [PaO2]/frac-
tion of inspired oxygen [FiO2] ratio less than 200) was 16.8% 
during the first 72 h after lung transplantation [12]. Accord-
ing to this study, pulmonary arterial hypertension before the 
surgery was a strong independent risk factor for the PGD, and 
the PGD was closely associated with mortality within one year 
after surgery. PGD manifests in the form of acute lung injury 
Table 1. Standard Lung Donor Criteria
Donor criteria
Age < 55 years
ABO compatibility
Clear chest radiograph
PaO2/FiO2 ratio > 300 mmHg, with PEEP 5 cmH2O
Cigarette smoking history of < 20 pack-years
Absence of significant chest trauma
No evidence of aspiration or sepsis
No prior thoracic surgery on side of harvest
Absence of organisms on sputum Gram stain
Absence of purulent secretions and gastric contents at bronchoscopy
Negative for HIV antibody, hepatitis B surface antigen, and hepatitis C 
antibody
No active or recent history of malignancy (excluding localized 
squamous or basal cell skin cancer, localized cervical cancer, 
and primary brain tumors with low metastatic potential and in the 
absence or invasive procedures to the brain and skull) 
No history of significant chronic lung disease
PaO2: partial pressure of oxygen, FiO2: fraction of inspired oxygen, 
PEEP: positive end-expiratory pressure, H2O: water, HIV: human immu-
nodeficiency virus. 
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(ALI). Oxidative stresses play an important role in the devel-
opment of ALI. Moreover, one-lung ventilation (OLV) during 
the lung transplantation induces ventilation perfusion mis-
match, which leads to hypoxic pulmonary vasoconstriction 
(HPV), a defensive mechanism of the body. HPV is known 
to be closely related to oxidative stress [13]. Oxidative stress 
is increased by reperfusion of the transplanted organs as 
well as by OLV, mechanical ventilation, and surgical trauma. 
These factors play an important role in the prognosis after 
surgery along with the inflammatory reaction during the lung 
transplantation [13,14]. Impaired cardiopulmonary function 
of the patient may cause difficulties during the administra-
tion of anesthesia. In addition to managing these difficulties, 
controlling pulmonary hypertension, oxidative stress, and 
inflammation during surgery is also an important part of the 
anesthetic care. More profound anesthesia is needed as it 
could have an important effect on prognosis.
PREOPERATIVE EVALUATION
Evaluation of the patient should be performed focusing on 
several factors including pulmonary, cardiac, psychological, 
infectious, nutritional, and social aspects. Participation and 
cooperation of a multidisciplinary team is essential for preop-
erative evaluation. The patients who are listed to receive lung 
transplantation often have to wait for a long time after the 
listing. Condition of the patient may worsen rapidly during 
this period, therefore, reexamination of the patient’s current 
condition should be carried out if necessary. The pulmonary 
reservoir of the patient can be predicted by arterial blood gas 
analysis and pulmonary function. A ventilation-perfusion (V/
Q) scan can accurately predict whether the patient can toler-
ate OLV during operation. If the perfusion of the non-opera-
tive lungs is less than 40% on the V/Q scan, hypoxemia may 
be aggravated during OLV. Refractory hemodynamic instabil-
ity may also occur after clamping of the pulmonary artery of 
the operative lung. A thorough review of the cardiac function 
and the degree of pulmonary hypertension is also essential. 
Pulmonary hypertension is considered an important inde-
pendent risk factor that influences the prognosis of patients 
after lung transplantation [12]. It is known that pulmonary hy-
pertension may develop with disease progression in various 
lung diseases that lead to ESLD [15]. Prevalence of pulmonary 
hypertension was close to 84% in the cases with IPF [16,17], 
which is the most common reason for lung transplantation 
in Korea. It has been reported that the mean pulmonary arte-
rial pressure increases to more than 20 mmHg in about 90% 
of the end-stage COPD patients [18]. Since the right ventricle 
(RV) is much more vulnerable to pressure overload than the 
left ventricle (LV), RV function can be impaired in ESLD pa-
tients with pulmonary hypertension. RV hypertrophy is easily 
accompanied by pressure overload to overcome afterload 
[19]. RV function can be estimated by several indicators such 
as myocardial performance index (MPI), systolic wave veloc-
ity (S’), isovolumic relaxation time (IVRT), and tricuspid an-
nular plane systolic excursion (TAPSE) using echocardiogra-
phy. MPI can be measured from tissue Doppler imaging. MPI 
can be calculated by the formula (isovolumic contraction 
time + isovolumic relaxation time)/ejection time. When the 
heart rate is < 70 or > 100 beats per minute, the MPI should be 
corrected. S’ is the velocity of the lateral annular movement 
during systole and can be measured from tissue Doppler 
imaging. IVRT is the time between closure of the pulmonary 
valve and opening of the tricuspid valve. It can be measured 
from tissue Doppler imaging of RV free wall. TAPSE is the 
total excursion of the tricuspid annulus between the highest 
position and the peak descent and can reflect RV longitudinal 
function. TAPSE can be measured using M-mode from the 
four-chamber view. Table 2 shows the interpretation of these 
parameters [20]. It is known that in 4–25% of patients, IPF is 
accompanied by coronary artery disease. Some studies have 
suggested that IPF-induced pro-inflammatory status is asso-
ciated with an increased incidence of cardiovascular disease 
[21]. Therefore, coronary angiography should be performed 
before the lung transplantation. It is especially important in 
Korea where IPF is a major reason for lung transplantation. It 
is estimated that 50–85% of IPF patients have gastroesopha-
geal reflux. Patients with gastroesophageal reflux require 
Table 2. RV Functional Measurement
Parameter Normal Intermediate Abnormal
RV MPI < 0.28 0.28–0.32 > 0.32
S’ wave of tricuspid 
annulus (cm.s−1)
> 12 11.5–12 < 11.5
IVRT (s) < 75 ≥ 75
TAPSE (ms) ≥ 20 16–20 < 16
RV: right ventricle, MPI: myocardial performance index, S’ wave: systolic 
wave, IVRT: isovolumic relaxation time, TAPSE: tricuspid annular plane 
systolic exertion. 
Anesthesia for lung transplantation
243www.anesth-pain-med.org
K
S
TA
medical or surgical treatment prior to the transplantation be-
cause of the increased risk of aspiration after transplantation 
[22].
MONITORING
Currently, there is no consensus guideline for intraopera-
tive monitoring during lung transplantation. However, most 
centers routinely use transesophageal echocardiography 
(TEE), pulmonary arterial catheter (PAC), and arterial line 
in addition to standard monitors. The insertion of the arte-
rial line should be performed prior to induction to quickly 
detect the hemodynamic changes during induction and 
to perform rapid intervention. The role and importance 
of TEE monitoring during lung transplantation is increas-
ing. The anesthesiologist can detect the change in RV and 
LV function through TEE monitoring. It helps the decision-
making regarding weaning of extracorporeal membrane 
oxygenation (ECMO) after surgery when ECMO is used for 
hemodynamic support in lung transplantation. Even when 
the operation is performed without ECMO, it can provide im-
portant information to help decide whether to insert ECMO 
for hemodynamic support during surgery. TEE also plays an 
important role in distinguishing the cause of hypoxemia after 
reperfusion. Clogging, kinking of the vessel, and narrowing 
of anastomosis can be ruled out if pulmonary vessel flow 
is confirmed through TEE. If the minimum diameter of the 
pulmonary artery anastomosis is greater than 75% of the di-
ameter of the proximal pulmonary artery and if the color flow 
Doppler flows through the anastomosis without obstruction, 
the pulmonary artery anastomosis is regarded as normal [23]. 
In the absence of obstruction of pulmonary vessel flow, acute 
graft rejection or reperfusion injury can be suspected. The air 
originating from the donated lung often enters the systemic 
circulation after reperfusion. Early detection of the regional 
wall motion abnormality is possible with TEE. It can also find 
out the cause of the abnormality by confirming the presence 
of air in the left atrium and the LV. PAC is useful for monitor-
ing the continuous cardiac output and the mixed venous 
saturation. Some centers insert the PAC before induction 
due to severe pulmonary hypertension and compromised 
right heart function. However our center prefers placing the 
PAC after intubation because most patients can’t tolerate 
the supine head-down position for the whole duration of 
the procedure. We routinely use cerebral oximetry for early 
detection of cerebral hypoxia and devices such as bispectral 
index monitor for assessing the depth of anesthesia. As hy-
pothermia can increase the pulmonary vascular resistance 
(PVR) and the chances of bleeding and infection, monitoring 
and maintenance of body temperature are essential [24,25]. 
As pulse oximetry is inaccurate under ECMO or cardiopul-
monary bypass (CPB), the adequacy of oxygenation should 
be judged synthetically through the results of mixed venous 
oxygen saturation, cerebral oximetry, and arterial blood gas 
analysis, in addition to pulse oximetry.
INDUCTION OF ANESTHESIA 
Induction is the most critical phase in anesthetic man-
agement. Despite adequate preoxygenation, desaturation 
progresses very quickly because of the lowered respiratory 
reserve in patients receiving lung transplants. Rapid desatu-
ration and hypercarbia can rapidly increase the PVR, which 
may result in RV failure, especially in patients with impaired 
RV function [26]. Moreover, suppression of sympathetic 
nervous system, decrease in systemic vascular resistance, 
myocardial depression by anesthetics, reduction of venous 
return, and increase of RV afterload by positive pressure ven-
tilation may cause severe hemodynamic compromise. There-
fore, ECMO or CPB should be kept ready for an emergency. 
The surgeon and the perfusionist should also be involved in 
the induction [27]. Midazolam, etomidate, propofol, and ket-
amine as hypnotics, and fentanyl and sufentanil as analgesics 
can be used as induction agents. The choice of the anesthetic 
agent and the determination of its dose for induction must be 
tailored to the patients’ condition. Lung transplant surgery 
requires a double lumen tube (DLT) similar to the other lung 
operations. Left-sided DLTs are preferred to right-sided ones 
because they are easier to mount and the bronchial tip of left-
sided DLT does not interfere with the bronchial anastomosis 
[28]. If the patient has a difficult airway, initial DLT intuba-
tion can be very dangerous. In such cases, it is better to place 
a single lumen tube first and then replace it with DLT using 
a tube exchanger. In our center, we perform femoral artery 
cannulation in addition to right radial artery cannulation for 
monitoring of systemic arterial pressure, the PAC insertion 
for monitoring of pulmonary arterial pressure, followed by 
the TEE insertion.
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HEMODYNAMIC AND RESPIRATORY 
SUPPORT DURING LUNG 
TRANSPLANTATION
After induction of anesthesia, ECMO or CPB is performed 
for hemodynamic and respiratory support during lung 
transplantation for the patients with moderate to severe pul-
monary hypertension or RV dysfunction. In Korea, IPF is the 
most common reason for lung transplantation and is com-
monly accompanied by pulmonary hypertension. Hence, our 
center has routinely applied ECMO or CPB during surgery. 
Although CPB has been the standard technique for intraoper-
ative cardiorespiratory support during the lung transplanta-
tion [29], results of various studies indicate that veno-arterial 
(VA) ECMO can be used as a substitute for CPB to provide 
intraoperative hemodynamic and respiratory support. Use of 
ECMO is associated with lower heparin doses and reduced 
blood activating surfaces due to lack of a venous reservoir 
and additional suction lines [30]. Thus, when compared with 
CPB, coagulopathy and inflammatory cascades are better at-
tenuated when ECMO is used. ECMO can easily be extended 
to postoperative care (during postoperative graft dysfunction) 
[30]. Since these advantages result in better outcomes [31], 
some European and North American centers have changed 
their primary intraoperative cardiopulmonary support tech-
nique from CPB to ECMO [30,32–35]. Since 2013, our center 
has performed lung transplantations using the peripheral VA 
ECMO technique [36].
MAINTENANCE OF ANESTHESIA
For maintenance of anesthesia, inhalation agents or pro-
pofol can be used with narcotic analgesics such as sufentanil 
or fentanyl. Although halothane induces HPV in a dose-de-
pendent manner, recent inhalation agents are not associated 
with HPV at concentrations used in lung transplantation [37]. 
In a recent systematic review comparing inhalation agents 
and intravenous anesthetics in patients undergoing OLV, no 
significant difference was found in the outcomes between 
the two types of drugs used for anesthesia [38]. However, 
OLV with patient’s native lung may negatively influence the 
uptake of an inhalation agent. Hence, total intravenous an-
esthesia (TIVA) may be more reliable in such cases. Recently, 
our center changed the maintenance protocol from balanced 
anesthesia (sevoflurane with sufentanil) to TIVA (propofol 
with sufentanil). 
During the surgical procedure, OLV with native lung may 
cause hypoxemia, hypercarbia, acidosis, and increase in PVR, 
which, in turn, may result in hemodynamic instability and RV 
failure. Therefore, appropriate ventilation strategy for OLV 
and hemodynamic and respiratory support using ECMO are 
essential. Increasing the positive end-expiratory pressure 
(PEEP) in the ventilated lung improves oxygenation by di-
verting the blood flow to the non-ventilated lung. However, 
slow titration is required in such cases [39]. Hyperinflation 
of the alveoli may increase the RV afterload and decrease 
the LV preload, which can result in severe hemodynamic 
compromise [40]. Especially, in patients with COPD or bron-
chiolitis obliterans syndrome, the exhalation time should be 
increased (inspiratory:expiratory ratio = 1:3–1:4) to minimize 
auto-PEEP and avoid hyperinflation [26]. If hypoxia contin-
ues during OLV, applying continuous positive airway pres-
sure with oxygen to a non-ventilated lung can temporarily 
improve oxygenation until the lung is removed. In addition 
to its role as a salvage therapy in ESLD patients, ECMO plays 
an essential role in regulating hypoxemia, hypoxia, and he-
modynamic instability during lung transplantation. Since 
our center routinely uses peripheral VA ECMO, the ventilator 
setting of OLV is as follows: Tidal volume is 4 ml per kg, respi-
ratory rate is 5 breaths per minute, the FiO2 for native lung is 
1.0, and the FiO2 for new lung after reperfusion is 0.21. Due to 
the nature of the peripheral VA ECMO, differential hypoxia 
may occur in the proximal ascending aorta, even when the 
estimated full flow is maintained [41]. Based on the gas analy-
sis results from the right radial artery, the ventilator setting is 
adjusted to maintain the PaO2 above 70 mmHg [41].
The ECMO protocol at our center is as follows. Before the 
initiation of the ECMO cannulation, a single, unfractionated 
heparin bolus targeting an activated clotting time between 
150–180 s is administered. VA ECMO using the Bioline 
heparin-coated Quadrox PLS circuit system primed with 0.8 
L acetated Ringer’s solution is performed with femoral artery-
femoral vein cannulation. An arterial cannula (15–17 Fr) for 
the arterial inflow is inserted into the common femoral artery 
via the percutaneous route using the cut-down method, fol-
lowed by insertion of a cannula (20–24 Fr) into the common 
femoral vein for the venous outflow. The ECMO blood flow 
is maintained at an estimated full flow (50 ml/kg/min) until 
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the end of surgical procedure. The FiO2 of the ECMO is main-
tained at 1.0 and the sweep gas rate is adjusted according to 
the arterial partial pressure of carbon dioxide from the arte-
rial blood gas analysis, which is around 40 mmHg.
Phosphodiesterase (PDE) 3 inhibitor (milrinone), PDE 5 
inhibitor (sildenafil), prostacyclin analogue (iloprost), and 
nitric oxide are known to decrease PVR and pulmonary artery 
pressure and to improve RV function [42–44]. At our center, 
0.5 μg/kg/min of milrinone is infused routinely in all patients 
after induction, and 20 μg of iloprost mixed with normal sa-
line (total 5 ml) is inhaled to each lung using an ultrasonic 
nebulizer for 20 to 30 min after reperfusion of each lung. A 
recent study has shown that intraoperative inhaled iloprost 
could prevent primary graft dysfunction and early post-trans-
plant morbidity in patients after lung transplantation [45].
As the lymphatic drainage is disrupted in the transplanted 
lungs, the alveolar fluid clearance is also impaired [46]. 
Therefore, the transplanted lung is very sensitive to fluid ad-
ministration. Fluid overload can cause pulmonary edema in 
such cases. Disruption of lymphatic drainage is also known 
to be one of the important pathophysiological mechanisms 
of PGD [46]. In a recent cohort study, increased fluid volume 
during surgery has been reported to be strongly associated 
with severe form of PGD [47].
MANAGEMENT AFTER REPERFUSION
Reperfusion is one of critical steps during lung transplanta-
tion. During reperfusion, the preservation solution filled in 
the donated lung is washed out and the de-airing process is 
performed. As sudden bleeding may occur in this process, 
volume replacement may be necessary [27,48]. Hypotension 
may also be caused by various metabolites from the donated 
ischemic lung after reperfusion. Some studies have reported 
that mannitol may be helpful as a scavenger of oxygen free 
radicals [49]. If the blood flow to the donated lung increases 
suddenly during the reperfusion process, mechanical sheer 
stress may be applied to the new endothelium. This leads to 
endothelial dysfunction, which is exacerbated by the reac-
tive oxygen species. As a result, microvascular permeability 
and pulmonary edema are increased, which are known to be 
important causes of PGD [50]. Such an ischemia/reperfusion 
injury can be mitigated by gradually increasing the pulmo-
nary circulation, which can be achieved by slowly decreasing 
the blood flow of the ECMO [51,52]. Although it is not known 
how to slow down the ECMO blood flow for weaning, slow 
weaning is thought to improve the prognosis of the patient 
with severe pulmonary hypertension.
After reperfusion, the anesthesiologist should confirm the 
patency of the bronchial anastomosis using a bronchoscope 
and the pulmonary vessel patency using the TEE. Immedi-
ately after reperfusion, ventilation of the transplanted lung 
should be started with low FiO2, low tidal volume, and slow 
respiratory rate. The tidal volume should be increased gradu-
ally to 4–5 ml/kg depending on the ideal body weight of the 
donor for OLV [53] and to 6 ml/kg for double-lung ventilation 
[54] according to the lung protective strategy. Several studies 
have shown that a high FiO2 after reperfusion is closely as-
sociated with the development of PGD [12]. Therefore, it is 
important to maintain the ventilation with FiO2 as low as pos-
sible while maintaining the PaO2 above 70 mmHg [55].
After the lung transplantation is complete, the DLT should 
be replaced with a single lumen tube. Since the airway after 
transplantation is usually edematous, it is necessary to use 
the exchange catheter and the direct or video-laryngoscopy 
together while performing the tube exchange.
CONCLUSION
Anesthesia for lung transplantation is one of the most chal-
lenging areas for an anesthesiologist. An anesthesiologist in-
volved in lung transplantation should be familiar with the use 
of ECMO and TEE and should understand the surgical tech-
nique and pathophysiology of ESLD. Close cooperation with 
all the teams involved in the lung transplantation is essential. 
It is important to remember that the anesthesiologist’s intra-
operative management can have a significant impact on the 
patient’s prognosis.
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